SCHEMBL3102839

SCHEMBL3102839

O=S(=O)(Nc1cccnc1Br)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.63
LMNA P02545 3/20 0.63
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
PGR P06401 3/20 0.52
KMT2A Q03164 3/20 0.52
ALDH1A1 P00352 2/20 0.52
POLB P06746 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MEN1 O00255 2/20 0.51
SLC40A1 Q9NP59 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
FFAR1 O14842 2/20 0.50
GLO1 Q04760 2/20 0.50
G6PD P11413 1/20 0.50
NFKBIA P25963 1/20 0.50
AGTR1 P30556 1/20 0.50
METAP2 P50579 1/20 0.50
METAP1 P53582 1/20 0.50
PAX8 Q06710 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28418785 0.85 SLC40A1 (0.68) LMNAHTTSMN1; SMN2KMT2APOLB
SCHEMBL8626115 0.81 TUBB4A (0.65) KDM4ELMNAHTTSMN1; SMN2PGR
SCHEMBL3109577 0.80 GLO1 (0.66) KDM4EKMT2AALDH1A1MEN1SLC40A1
SCHEMBL20571831 0.80 KMT2A (0.66) KDM4ELMNAHTTSMN1; SMN2KMT2A
SCHEMBL2704942 0.80 SLC40A1 (0.66) KDM4ELMNAKMT2AALDH1A1POLB
SCHEMBL8009202 0.79 KMT2A (0.65) KDM4ELMNAPGRKMT2AALDH1A1
SCHEMBL8626225 0.76 TUBB4A (0.78) KDM4ELMNAHTTSMN1; SMN2PGR
SCHEMBL5595259 0.76 PGR (0.59) KDM4ELMNASMN1; SMN2PGRKMT2A
SCHEMBL2740131 0.74 KDM4E (0.50) KDM4ELMNAHTTSMN1; SMN2KMT2A
SCHEMBL5898975 0.73 MMP2 (0.64) KDM4ELMNAHTTSMN1; SMN2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100279986-A1 HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2010-11-04 US disclosed
US-7803793-B2 Heterocyclic derived metalloprotease inhibitors JANSSEN PHARMACEUTICA NV (BE) 2010-09-28 US disclosed
US-20080103129-A1 HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103129-A1 HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS ADAM17, MMP25, ADAM33 KDM4E 1117/4885LMNA 1019/4885HTT 1950/4885
US-20100279986-A1 HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS ADAM17, MMP25, ADAM33 KDM4E 1117/4885LMNA 1019/4885HTT 1950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.